spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Gaucher Disease 

 HSMN NewsFeed - 12 Sep 2023
Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Jul 2021
Coave Therapeutics Closes €33 million ($39 million) Series B Financing to Develop its Gene Therapy Pipeline and Next-Generation Vectors based on its AAV-Ligand Conjugate Platform
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 22 Jan 2021
Lilly Completes Acquisition of Prevail Therapeutics
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 15 Dec 2020
Lilly Announces Agreement to Acquire Prevail Therapeutics
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 10 Mar 2020
CytRx Corporation Provides Update on Management Change
Biopharmaceuticals Oncology Neurology Personnel
 HSMN NewsFeed - 19 Dec 2019
Protalix BioTherapeutics Adds Two Accomplished Biopharmaceutical Executives to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Apr 2018
Amerigen and Dipharma Announce U.S. FDA Approval for Generic Miglustat 100 mg Capsules
Biopharmaceuticals Generics FDA Product Launch
 HSMN NewsFeed - 8 Feb 2016
Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS I
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Dec 2015
Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-FIX, First In Vivo Protein Replacement Platform Program For Treatment Of Hemophilia B
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Jun 2014
Protalix Announces New Data on ELELYSO(TM) (taliglucerase alfa) Presented at the European Working Group on Gaucher Disease 2014 11th Meeting
Biopharmaceuticals
 HSMN NewsFeed - 12 May 2014
Lysosomal Therapeutics Inc. Receives $4.8 Million in Seed Funding
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 11 Dec 2013
FDA Grants Priority Review for Genzyme’s Cerdelga(TM) (eliglustat), an Investigational Oral Therapy for Gaucher Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Apr 2013
UPLYSO(TM) (alfataliglicerase) Approved in Mexico and Chile for the Treatment of Gaucher Disease
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 15 Feb 2013
Genzyme Announces Positive New Data from Two Phase 3 Studies for Oral Eliglustat Tartrate for Gaucher Disease
Biopharmaceuticals
 HSMN NewsFeed - 6 Dec 2012
Protalix BioTherapeutics Signs Clinical Development Agreement With Pfizer for ELELYSO(TM) (taliglucerase alfa)
Biopharmaceuticals
 HSMN NewsFeed - 27 Jun 2012
Alnylam Expands and Develops Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 May 2012
Pfizer And Protalix BioTherapeutics Announce FDA Approval Of ELELYSO(TM) (taliglucerase alfa) For The Treatment Of Gaucher Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Sep 2011
NPS Pharmaceuticals Appoints Eric Pauwels as Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Apr 2011
Raptor Pharmaceutical Adds Three Biopharmaceutical Leaders to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Feb 2011
FDA Issues Complete Response Letter for Taliglucerase Alfa New Drug Application
Biopharmaceuticals
 HSMN NewsFeed - 29 Nov 2010
Pfizer and Protalix BioTherapeutics Announce Submission of taliglucerase alfa for European Marketing Authorization for the Treatment of Gaucher Disease
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 7 Sep 2010
Protalix BioTherapeutics Names Tzvi Palash Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Aug 2010
Genzyme Confirms Receipt of Unsolicited Proposal
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 22 Dec 2009
Shire Submits Biologics License Application (BLA) for REPLAGAL(R) With the U.S. Food and Drug Administration (FDA)
Biopharmaceuticals
 HSMN NewsFeed - 17 Dec 2009
Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Sep 2009
FDA Grants Protalix Orphan Drug Designation for prGCD
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Aug 2009
Protalix Receives FDA Fast Track Designation for prGCD
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Aug 2009
Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Jul 2009
Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Jun 2009
William Aliski Named FoldRx Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jan 2009
Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Dec 2007
Protalix BioTherapeutics Announces Resignation of Board Members
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Nov 2007
Amicus Therapeutics and Shire plc Enter Into $440 Million ex-US Licensing Agreement to Develop and Commercialize Amigal(TM), Plicera(TM) and At2220
Biopharmaceuticals Licensing
 HSMN NewsFeed - 8 Nov 2007
Shire Expands its Human Genetic Therapies Pipeline Through In-Licensing Agreement With Amicus Therapeutics
Biopharmaceuticals Licensing
 HSMN NewsFeed - 19 Oct 2007
Actelion Ltd: Miglustat (Zavesca) Receives Negative Opinion From the European Committee For Medicinal Products For Human Use For Extension of Indication For Niemann Pick Type C
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 4 Oct 2007
Genzyme Receives Approval to Market Elaprase(R) in Japan
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Aug 2007
Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
Biopharmaceuticals
 HSMN NewsFeed - 16 May 2007
Genzyme Announces Positive Initial Observations in Trial Evaluating Novel Oral Treatment for Gaucher Disease
Biopharmaceuticals
 HSMN NewsFeed - 18 Apr 2007
Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Mar 2007
Amicus Therapeutics Announces Return of John F. Crowley as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Mar 2007
Orthodontix Announces Name Change to Protalix BioTherapeutics, Inc.
Biopharmaceuticals
 HSMN NewsFeed - 23 Jan 2007
Amicus Therapeutics Receives Grant From Michael J. Fox Foundation for Parkinson's Research
Biopharmaceuticals Neurology
 HSMN NewsFeed - 15 Jan 2007
Genzyme Announces Publication of Study Showing Impact of Cerezyme on Bone Health for Patients With Type 1 Gaucher Disease
Biopharmaceuticals
 HSMN NewsFeed - 2 Oct 2006
Amicus Therapeutics Appoints Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Sep 2006
Teva Pharmaceutical Industries Ltd. and Protalix Biotherapeutics Ltd. Announce a Collaboration Agreement for the Development of Two Biopharmaceuticals, Based on Protalix's Recombinant Plant Cell Expression Technology
Biopharmaceuticals Licensing
 HSMN NewsFeed - 14 Sep 2006
Amicus Therapeutics Raises $60 Million Series D Financing; Company Also Makes Two Key Executive Appointments
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 5 Jul 2006
Amicus Therapeutics Adds Glenn P. Sblendorio to Board of Directors
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 21

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 21 additional stories matching:
Gaucher Disease
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.